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Background and Purpose: Malformation of cortical development (MCD) is a well-known cause of 
drug-resistant epilepsy and focal cortical dysplasia (FCD) is the most common neuropathological finding 
in surgical specimens from drug-resistant epilepsy patients. Palmini’s classification proposed in 2004 is 
now widely used to categorize FCD. Recently, however, Blumcke et al. recommended a new system for 
classifying FCD in 2011.
Methods: We applied the new classification system in practical diagnosis of a sample of 117 patients 
who underwent neurosurgical operations due to drug-resistant epilepsy at Severance Hospital in Seoul, 
Korea.
Results: Among 117 cases, a total of 16 cases were shifted to other FCD subtypes under the new 
classification system. Five cases were reclassified to type IIIa and five cases were categorized as dual 
pathology. The other six cases were changed within the type I category.
Conclusions: The most remarkable changes in the new classification system are the advent of dual 
pathology and FCD type III. Thus, it will be very important for pathologists and clinicians to discriminate 
between these new categories. More large-scale research needs to be conducted to elucidate the 
clinical influence of the alterations within the classification of type I disease. Although the new FCD 
classification system has several advantages compared to the former, the correlation with clinical 
characteristics is not yet clear. (2012;2:38-42)
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Introduction
Malformation of cortical development (MCD) is a well-known 
cause of drug-resistant epilepsy. More specifically, focal cortical 
dysplasia (FCD), a localized form of MCD, is thought to be the 
most common neuropathological finding in drug-resistant epilepsy 
patients following attempted curative neurosurgery. FCD was first 
described by Taylor et al. in 19711 who delineated specific microscopic 
findings such as cortical disorganization, bizarre neurons, and 
balloon cells, among other features, in ten drug-resistant epilepsy 
patients. Since then, although many classification systems have been 
proposed by neuropathologists and clinicians,2-5 the pathogenesis, 
etiology, and clinical characteristics of FCD are still relatively unclear.
Currently, Palmini’s classification system, proposed in 2004, is 
widely used to categorize FCD. According to this system, cortical 
dyslamination is a common characteristic of FCD, regardless of 
subtype. Type Ia is defined as cortical dyslamination only, while 
the designation of types Ib, IIa, and IIb are given when additional 
cytoarchitectural abnormalities are present such as giant or 
immature neurons, dysmorphic neurons, and balloon cells.4 Although 
Palmini’s system is commonly applied in diagnosis, it has inherent 
flaws. According to Palmini’s system, the radiologic characteristics of 
FCD may be diverse even within a given subtype.6,7 Moreover, 
histologic examination cannot guarantee reliability in diagnosis, 
particularly when the FCD pathology is mild.8
In 2011, Blumcke et al.9 recommended a new classification system 
for FCD. The most striking change in the new classification system is 
the incorporation of a three-tiered system. FCD associated with other 
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Table 1. Palmini’s classification system of cortical dysplasia
Type Subtype Main neuropathological features
Mild MCD Type I Heterotopic/excess neurons in layer I
Type II Heterotopic/excess neurons outside layer I
FCD type I Type Ia Cortical dyslamination only
Type Ib Cortical dyslamination+giant or immature neurons
FCD type II (Taylor-type) Type IIa Cortical dyslamination+dysmorphic neurons
Type IIb Cortical dyslamination+dysmorphic neurons and balloon cells
MCD, malformation of cortical development; FCD, focal cortical dysplasia.
principal lesions is denoted to be type III and is further divided into 
four categories according to the associated principal lesions.9 The 
principal lesions include hippocampal sclerosis, tumorous conditions 
such as glioneuronal tumors or dysembryoplastic neuroectodermal 
tumors, vascular malformations, and acquired lesions induced by 
trauma, ischemic injury, and encephalitis. In addition, the definition 
of FCD type I has been changed according to the new system. The 
cortical dyslamination that was used to describe FCD type I in 
Palmini’s system is a vague definition, which can result in inter-
personal communication errors. In contrast, Blumcke et al. divided 
cortical dyslamination into two subcategories: abnormal radial 
lamination and abnormal tangential lamination.9 The former is 
classified as type Ia and the latter as type Ib. The diagnosis of type Ic 
can be made when both radial and tangential cortical dyslamination 
are detected. Herein, we will apply the new classification system of 
FCD to practical diagnosis.
Methods
Case enrollment
Cases included 117 patients with cortical dysplasia who were 
histologically proven after neurosurgery due to drug-resistant 
epilepsy between May 2003 to March 2011 at Severance Hospital in 
Seoul, Korea. All clinical information was investigated by reviewing 
the electronic medical records of Severance Hospital.
Pathologic approach
In cases where surgical specimens are taken from epilepsy 
patients, it is often difficult for pathologists to identify the margins of 
lesions. Therefore, all brain specimens submitted were reexamined 
on formalin-fixed, paraffin-embedded tissue cut perpendicular to the 
pia matter. Sections were dissected at intervals of four micrometers 
and stained with hematoxylin and eosin. All slides from the cases 
were independently reviewed by a neuropathologist and a general 
pathologist.
The initial diagnoses were reviewed according to the classification 
system of Palmini (Table 1). Cases described before 2004, when 
Palmini first proposed the classification of FCD, were initially 
reclassified according to Palmini’s classification system. For example, 
cases diagnosed as “neurons in white matter” or “presence of 
dysmorphic neurons” were reclassified as MCD type II and FCD type 
IIa, respectively. Pathological specimens were then reclassified 
according to Blumcke’s new classification system (Table 2).
Terminology
“Dysmorphic neurons” are random in orientation and have 
abnormal dendritic processes and high Nissle substance concentrations 
(Figure 1A).4 “Balloon cells” are large cellular elements with glassy 
eosinophilic cytoplasm and eccentric nuclei (Figure 1B).4 “Micro-
columns” are defined by the vertical alignment of at least eight small 
neurons.10 The presence of microcolumns can be confirmed through 
NeuN immunohistochemistry. “Dual pathology” is applied when 
additional findings exist separately, unrelated to cortical dysplasia.9 
Results
The patient sample consisted of 71 males and 46 females 
(M:F=1.54:1) with an age range of two months to 24 years. The 
mean age was 8.09 years. According to Palmini’s classification 
system, 44 patients were classified as having MCD, six as FCD 
type Ia, eight as FCD type Ib, 36 as FCD type IIa, and 23 as FCD type 
IIb. When reclassified by Blumcke’s new classification system, 7 
(15.91%) of 44 MCD cases, 5 (83.33%) of 6 FCD type Ia cases, 
1 (12.50%) of 8 FCD type Ib cases, 2 (5.56%) of 36 FCD type IIa 
cases, and 1 (4.35%) of 23 FCD type IIb cases were reclassified to 
other subtypes (Table 3).
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Table 2. Blumcke’s classification system of focal cortical dysplasia
FCD type I (isolated)
FCD type Ia FCD type Ib FCD type Ic
Focal cortical dysplasia with abnormal radial 
cortical lamination
Focal cortical dysplasia with abnormal 
tangential cortical lamination
Focal cortical dysplasia with abnormal radial 
and tangential cortical lamination
FCD type II (isolated)
FCD type IIa FCD type IIb
Focal cortical dysplasia with
dysmorphic neurons
Focal cortical dysplasia with
dysmorphic neurons and balloon cells
FCD type III (associated with principal lesion)
FCD type IIIa FCD type IIIb FCD type IIIc FCD type IIId
Cortical lamination abnormalities 
in the temporal lobe associated 
with hippocampal sclerosis
Cortical lamination abnormalities 
adjacent to a glial or 
glioneuronal tumor
Cortical lamination abnormalities 
adjacent to vascular 
malformation
Cortical lamination abnormalities 
adjacent to any other lesion acquired
during early life, e.g., trauma, 
ischemic injury, encephalitis
FCD, focal cortical dysplasia.
 
Figure 1. Dysmorphic neurons (A) and balloon cells (B) of focal cortical dysplasia in type IIa and IIb, respectively (hematoxylin and eosin, original 
magnification, ×200).
Among the 16 reclassified cases, MCD was found to be the most 
common initial diagnosis. Most cases were reclassified to FCD type 
IIIa, which is associated with hippocampal sclerosis. Two of seven 
MCD cases and three type II FCD cases were redesignated to dual 
pathology due to the presence of separately located hippocampal 
sclerosis, tumors, and vascular malformation.
The clinical characteristics of the reclassified cases and factors 
influencing reclassification are summarized in Table 4.
Discussion 
FCD is the most common cause of drug-resistant epilepsy. Thus, 
neuropathologists and clinicians have proposed many classification 
systems for FCD.2-5 We applied the new classification system 
suggested by Blumcke in 2011 to practical diagnosis and considered 
its advantages and limitations. 
MCD was found to be the most commonly recategorized subtype 
by the new classification system, accounting for seven out of 16 
cases. However, two out of seven cases were reassigned to dual 
pathology, rather than only recategorized. As the definitions of type I 
FCD in two classification systems differ from each other, the 
proportion of recategorized cases within this group (42.86%) is 
substantial. This may be explained, as Blumcke et al. subdivided 
cortical dyslamination into two detailed categories. However, as the 
subdivision is purely based on morphologic criteria, it is unclear 
whether the change in FCD type I has any clinical significance. 
Furthermore, giant neurons and immature neurons are no longer 
incorporated into grouping criteria. Nevertheless, those characteristics 
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Table 3. Proportion of reclassified cases
Previous diagnosis Number of cases
Mean age
(yrs)
Sex (M:F)
Number of 
remainders (A)
Number of 
reclassified cases (B)
Proportion (B/[A+B]) 
(%)
MCD 44 8.46 1.18:1 37 7 15.91
FCD Ia 6 7.22 2:1 1 5 83.33
FCD Ib 8 9.80 5:1 7 1 12.50
FCD IIa 36 7.88 1.85:1 34 2 5.56
FCD IIb 23 7.39 1.5:1 22 1 4.35
Total 117 8.09 1.54:1 101 16 13.68
MCD, malformation of cortical development; FCD, focal cortical dysplasia.
Table 4. Clinical information on reclassified cases and causes of reclassification 
Case Age Sex Previous diagnosis Reclassified diagnosis Causes of reclassification
1 12 y M MCD* FCD†IIIa Hippocampal sclerosis
2 15 y 7 m M MCD FCD IIIa Hippocampal sclerosis
3 12 y 10 m M MCD FCD IIIa Hippocampal sclerosis
4 16 y 4 m M MCD FCD IIIa Hippocampal sclerosis
5 5 y 1 m M MCD FCD IIIa Hippocampal sclerosis
6 12 y 1 m M MCD Dual pathology Meningioma
7 17 y F MCD Dual pathology Cavernous hemangioma
8 6 y 8 m M FCD Ia FCD Ib By definition
9 1 y 10 m M FCD Ia FCD Ib By definition
10 2 m M FCD Ia FCD Ib By definition
11 6 y 1 m M FCD Ia FCD Ib By definition
12 10 y 5 m F FCD Ia FCD Ib By definition
13 1 y 8 m M FCD Ib FCD Ia By definition
14 11 y 3 m M FCD IIa Dual pathology Hippocampal sclerosis
15 5 y 11 m M FCD IIa Dual pathology Ganglioglioma
16 10 m F FCD IIb Dual pathology Hippocampal sclerosis
MCD, malformation of cortical development; FCD, focal cortical dysplasia.
should not be disregarded because there are no established clinical 
data associated with the presence of giant and immature neurons. 
Notably, FCD type Ib comprised a large proportion of the reclassi-
fication of FCD type I. This may be rooted in the narrow definition of 
microcolumns, which are necessary to diagnose FCD type Ia. Despite 
immunohistochemical support, microcolumnar arrangement is 
difficult to find.
Distinguishing between dual pathology and type III FCD may be 
unclear at times. When the cortical dyslamination is subtle and 
principal lesions are located within the same lobe (mostly temporal), 
type III can be preferred over dual pathology. In contrast, when 
obvious pathologic findings such as dysmorphic neurons or balloon 
cells are noted, type III should not be considered without evidence of 
distinct association. Gangliogliomas are brain tumors that are 
commonly associated with cortical dysplasia. In the case with a 
ganglioglioma, however, we could not include the case as type III 
because the tumor was small (about 2 cm) and an incidental finding. 
Similarly, cases with meningioma and cavernous hemangioma were 
categorized as dual pathology since the lesions were unrelated to 
cortical dysplasia. As discrimination between dual pathology and 
type III is critical to the clinical approach, pathologists must 
differentiate between the two subtypes.
Hippocampal sclerosis was the leading cause of reclassification. 
Most cases with hippocampal sclerosis were diagnosed as FCD 
type IIIa, except for two cases that were considered dual pathology. 
Significant clinical and radiological differences were found between 
isolated FCD type I and FCD type I associated with hippocampal 
sclerosis or tumor.11 Thus, it was important that cases shifted 
classification to FCD type IIIa as the presence of hippocampal 
sclerosis is likely meaningful.
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There were several cases of patients with congenital neuro-
developmental disorders such as Sturge-Weber syndrome and 
tuberous sclerosis. They were not included in FCD type IIId, since 
the subtype can only be diagnosed when acquired events are 
present. Thus, patients with congenital syndromes might be overlooked 
with this classification. There were cases with encephalomalacia, 
leukomalacia, gliosis, and mild hypoxic damage, most of which 
suspect the category of FCD type IIId. If there are any perinatal or 
acquired histories available, we could have put them in type IIId.
In this study, there were no cases categorized as type Ic, IIIb, IIIc, 
or IIId. As we only analyzed 117 cases from a single institute, further 
large-scale studies are required to establish the proportion of those 
subtypes. Although the new FCD classification system has several 
advantages compared to the former, the correlation with clinical 
characteristics is not yet clear.
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